Low-dose adjunctive cilostazol in patients with complex lesions undergoing percutaneous coronary intervention

Xin Tian Zheng, Kang Yin Chen, Tong Liu, Ling Xia Xu, Jing Jin Che, Seung-Woon Rha, Guang Ping Li

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Patients with complex coronary lesions undergoing percutaneous coronary intervention (PCI) have more major adverse cardiac events (MACE) than do those with simpler cases. Therefore, intensive antiplatelet therapy might be needed in these patients. A total of 127 patients with complex lesions undergoing PCI in the Second Hospital of Tianjin Medical University from October 2012 to April 2014 were randomized to receive either dual (aspirin plus clopidogrel, DAPT, n = 66), or triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol; TAPT, n = 61). Patients in the TAPT group received low-dose cilostazol (100 mg loading, followed with 50 mg twice per day) for 3-6 months. The primary endpoint was composite MACE. The complex coronary target lesions were defined as at least one of the following: left main disease; severe 3-vessel disease; chronic total occlusion lesions; true bifurcation lesion; ostial lesions; severe calcified lesions; and highly thrombotic lesions. The two groups had similar baseline clinical and angiographic characteristics. One-year clinical outcomes showed that the TAPT group had significantly lower incidences of myocardial infarction (1.6% vs 13.6%, P = 0.018) and MACE (1.6% vs 16.7%, P = 0.004) than DAPT group. The DAPT group had two cases of stent thrombosis, while the TAPT group did not. Furthermore, adjunctive low-dose cilostazol didn't significantly increase the incidence of bleeding events (26.2% vs 19.7%, P = 0.381) regardless of major (4.9% vs 4.5%, P = 0.921) or minor (21.3% vs 15.2%, P = 0.368) bleeding events. In conclusion, low-dose adjunctive cilostazol seems superior to dual antiplatelet therapy in reducing recurrent ischemic events in patients with complex coronary lesions and the two test groups have a similar incidence of bleeding events.

Original languageEnglish
Pages (from-to)29-33
Number of pages5
JournalClinical and Experimental Pharmacology and Physiology
Volume43
Issue number1
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Percutaneous Coronary Intervention
clopidogrel
Hemorrhage
Aspirin
Incidence
Stents
Thrombosis
Therapeutics
Myocardial Infarction
cilostazol
tyrosine-4-azophenyltrimethylammonium chloride

Keywords

  • Cilostazol
  • Complex coronary lesions
  • Dual antiplatelet therapy
  • Percutaneous coronary intervention
  • Triple antiplatelet therapy

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)
  • Pharmacology

Cite this

Low-dose adjunctive cilostazol in patients with complex lesions undergoing percutaneous coronary intervention. / Zheng, Xin Tian; Chen, Kang Yin; Liu, Tong; Xu, Ling Xia; Che, Jing Jin; Rha, Seung-Woon; Li, Guang Ping.

In: Clinical and Experimental Pharmacology and Physiology, Vol. 43, No. 1, 01.01.2016, p. 29-33.

Research output: Contribution to journalArticle

Zheng, Xin Tian ; Chen, Kang Yin ; Liu, Tong ; Xu, Ling Xia ; Che, Jing Jin ; Rha, Seung-Woon ; Li, Guang Ping. / Low-dose adjunctive cilostazol in patients with complex lesions undergoing percutaneous coronary intervention. In: Clinical and Experimental Pharmacology and Physiology. 2016 ; Vol. 43, No. 1. pp. 29-33.
@article{acb21e6adcb54a52a940b0efb50e576f,
title = "Low-dose adjunctive cilostazol in patients with complex lesions undergoing percutaneous coronary intervention",
abstract = "Patients with complex coronary lesions undergoing percutaneous coronary intervention (PCI) have more major adverse cardiac events (MACE) than do those with simpler cases. Therefore, intensive antiplatelet therapy might be needed in these patients. A total of 127 patients with complex lesions undergoing PCI in the Second Hospital of Tianjin Medical University from October 2012 to April 2014 were randomized to receive either dual (aspirin plus clopidogrel, DAPT, n = 66), or triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol; TAPT, n = 61). Patients in the TAPT group received low-dose cilostazol (100 mg loading, followed with 50 mg twice per day) for 3-6 months. The primary endpoint was composite MACE. The complex coronary target lesions were defined as at least one of the following: left main disease; severe 3-vessel disease; chronic total occlusion lesions; true bifurcation lesion; ostial lesions; severe calcified lesions; and highly thrombotic lesions. The two groups had similar baseline clinical and angiographic characteristics. One-year clinical outcomes showed that the TAPT group had significantly lower incidences of myocardial infarction (1.6{\%} vs 13.6{\%}, P = 0.018) and MACE (1.6{\%} vs 16.7{\%}, P = 0.004) than DAPT group. The DAPT group had two cases of stent thrombosis, while the TAPT group did not. Furthermore, adjunctive low-dose cilostazol didn't significantly increase the incidence of bleeding events (26.2{\%} vs 19.7{\%}, P = 0.381) regardless of major (4.9{\%} vs 4.5{\%}, P = 0.921) or minor (21.3{\%} vs 15.2{\%}, P = 0.368) bleeding events. In conclusion, low-dose adjunctive cilostazol seems superior to dual antiplatelet therapy in reducing recurrent ischemic events in patients with complex coronary lesions and the two test groups have a similar incidence of bleeding events.",
keywords = "Cilostazol, Complex coronary lesions, Dual antiplatelet therapy, Percutaneous coronary intervention, Triple antiplatelet therapy",
author = "Zheng, {Xin Tian} and Chen, {Kang Yin} and Tong Liu and Xu, {Ling Xia} and Che, {Jing Jin} and Seung-Woon Rha and Li, {Guang Ping}",
year = "2016",
month = "1",
day = "1",
doi = "10.1111/1440-1681.12495",
language = "English",
volume = "43",
pages = "29--33",
journal = "Clinical and Experimental Pharmacology and Physiology",
issn = "0305-1870",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Low-dose adjunctive cilostazol in patients with complex lesions undergoing percutaneous coronary intervention

AU - Zheng, Xin Tian

AU - Chen, Kang Yin

AU - Liu, Tong

AU - Xu, Ling Xia

AU - Che, Jing Jin

AU - Rha, Seung-Woon

AU - Li, Guang Ping

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Patients with complex coronary lesions undergoing percutaneous coronary intervention (PCI) have more major adverse cardiac events (MACE) than do those with simpler cases. Therefore, intensive antiplatelet therapy might be needed in these patients. A total of 127 patients with complex lesions undergoing PCI in the Second Hospital of Tianjin Medical University from October 2012 to April 2014 were randomized to receive either dual (aspirin plus clopidogrel, DAPT, n = 66), or triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol; TAPT, n = 61). Patients in the TAPT group received low-dose cilostazol (100 mg loading, followed with 50 mg twice per day) for 3-6 months. The primary endpoint was composite MACE. The complex coronary target lesions were defined as at least one of the following: left main disease; severe 3-vessel disease; chronic total occlusion lesions; true bifurcation lesion; ostial lesions; severe calcified lesions; and highly thrombotic lesions. The two groups had similar baseline clinical and angiographic characteristics. One-year clinical outcomes showed that the TAPT group had significantly lower incidences of myocardial infarction (1.6% vs 13.6%, P = 0.018) and MACE (1.6% vs 16.7%, P = 0.004) than DAPT group. The DAPT group had two cases of stent thrombosis, while the TAPT group did not. Furthermore, adjunctive low-dose cilostazol didn't significantly increase the incidence of bleeding events (26.2% vs 19.7%, P = 0.381) regardless of major (4.9% vs 4.5%, P = 0.921) or minor (21.3% vs 15.2%, P = 0.368) bleeding events. In conclusion, low-dose adjunctive cilostazol seems superior to dual antiplatelet therapy in reducing recurrent ischemic events in patients with complex coronary lesions and the two test groups have a similar incidence of bleeding events.

AB - Patients with complex coronary lesions undergoing percutaneous coronary intervention (PCI) have more major adverse cardiac events (MACE) than do those with simpler cases. Therefore, intensive antiplatelet therapy might be needed in these patients. A total of 127 patients with complex lesions undergoing PCI in the Second Hospital of Tianjin Medical University from October 2012 to April 2014 were randomized to receive either dual (aspirin plus clopidogrel, DAPT, n = 66), or triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol; TAPT, n = 61). Patients in the TAPT group received low-dose cilostazol (100 mg loading, followed with 50 mg twice per day) for 3-6 months. The primary endpoint was composite MACE. The complex coronary target lesions were defined as at least one of the following: left main disease; severe 3-vessel disease; chronic total occlusion lesions; true bifurcation lesion; ostial lesions; severe calcified lesions; and highly thrombotic lesions. The two groups had similar baseline clinical and angiographic characteristics. One-year clinical outcomes showed that the TAPT group had significantly lower incidences of myocardial infarction (1.6% vs 13.6%, P = 0.018) and MACE (1.6% vs 16.7%, P = 0.004) than DAPT group. The DAPT group had two cases of stent thrombosis, while the TAPT group did not. Furthermore, adjunctive low-dose cilostazol didn't significantly increase the incidence of bleeding events (26.2% vs 19.7%, P = 0.381) regardless of major (4.9% vs 4.5%, P = 0.921) or minor (21.3% vs 15.2%, P = 0.368) bleeding events. In conclusion, low-dose adjunctive cilostazol seems superior to dual antiplatelet therapy in reducing recurrent ischemic events in patients with complex coronary lesions and the two test groups have a similar incidence of bleeding events.

KW - Cilostazol

KW - Complex coronary lesions

KW - Dual antiplatelet therapy

KW - Percutaneous coronary intervention

KW - Triple antiplatelet therapy

UR - http://www.scopus.com/inward/record.url?scp=84954413926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954413926&partnerID=8YFLogxK

U2 - 10.1111/1440-1681.12495

DO - 10.1111/1440-1681.12495

M3 - Article

VL - 43

SP - 29

EP - 33

JO - Clinical and Experimental Pharmacology and Physiology

JF - Clinical and Experimental Pharmacology and Physiology

SN - 0305-1870

IS - 1

ER -